EXPERTISE

A knowledge centre
with a global scientific
engagement

Primarily a scientific research institute, CELICA BIOMEDICAL strives to provide groundbreaking research and medical applications in the fields of neuroscience and oncology treatments.

CELICA BIOMEDICAL was established with a mission to pursue biomedical research and to efficiently transform findings into products and services that address significant challenges in biomedicine.

The key activities of CELICA BIOMEDICAL are the development of research technologies for the assessment of single-cell function, services related to confocal microscopy, scientific research in neuroglia, the development of technologies for the production of hybrid cells for use in cancer therapy through immunomodulation, and the development of new neurologic treatments based on targeting neuroglia.

Since 2000 CELICA BIOMEDICAL has been receiving funds from the Slovenian Research Agency and been actively engaged in the National Research Programme together with the Medical Faculty of the University of Ljubljana. CELICA BIOMEDICAL is a regular member of international projects such as those funded by the National Institute of Health (USA) and Framework Programme projects funded by the EU. CELICA BIOMEDICAL is a partner of Edu-GLIA, an Initial Training Network (ITN) funded by the European Commission under the Seventh Framework Programme (FP7).

CELICA BIOMEDICAL laboratories operate under a quality management system in compliance with the SIST EN ISO/IEC 17025:2005 standard.

RESEARCH

A high quality scientific
environment for targeted
research and clinical trials.

CELICA BIOMEDICAL’s research facilities originate from the 1987 Cambridge-NARIP® project that was started to elucidate the mechanisms of regulated exocytosis. In the process, a new technology for monitoring regulated exocytosis was developed and resulted in a milestone publication in Nature (Lledo et al., 1993) and in Nature Protocols (Rituper et al., 2013).

The CELICA BIOMEDICAL research team collaborates closely with the Molecular Cell Physiology Lab at the University of Ljubljana, carrying out basic research projects aimed at understanding single-cell functioning and molecular events at subcellular organelle physiology level.

Techniques employed range from confocal microscopy, electrophysiology (capacitance measurements, Cambridge-NARIP® project), cytosolic calcium, cAMP, glucose, lactate measurements to molecular biology and others.

Since 2006, CELICA BIOMEDICAL has been operating a Carl Zeiss Reference Centre for Confocal Microscopy that is equipped with two LSM510 microscopes, one with a Faraday cage and the other with a Meta PMT array detector. Super-sensitive cameras are used in the Elyra platform for super-resolution microscopy. Image analysis is performed using the custom-made software packages Particle TR, Particle CO, ColocANA, CELL and others.

DEVELOPMENT

Breakthrough clinical
solutions for cancer
and neurological
diseases

CELICA BIOMEDICAL develops proprietary new technologies for research into physiological processes at the level of a single cell. The company also develops new therapies for neurological applications and advanced cell-based medical products to be used in personalised medicine.


Breakthrough clinical
solutions for cancer
and neurological
diseases

CELICA BIOMEDICAL develops proprietary new technologies for research into physiological processes at the level of a single cell. The company also develops new therapies for neurological applications and advanced cell-based medical products to be used in personalised medicine.

Advanced Cell-Based Medical Products: HybriCure®

HybriCure® was developed with proprietary electrofusion technology that is designed to treat cancer. It consists of fused-tumour and antigen-presenting cells.

For detailed information, please order a status report at:

Neuroprotection and Neurotreatment: SmartCure® Glia

The results of in-house research have established that SMART pharmacological agents (patented) robustly prevent pathological responses by neuroglia and are aimed at treating cognitive disorders, tissue response to trauma, Alzheimer's disease, multiple sclerosis and others.

For detailed information, please order a status report at:

Research technologies design

CELICA BIOMEDICAL has, together with partners, developed innovative research technologies that have been used in basic research for more than 30 years. The performance and applicability of the instruments developed are guaranteed by certificates gained and numerous papers published in peer-reviewed journals.

Partners

Slovenian Research Agency, Carl Zeiss Reference Centre, Lek Pharmaceutical Company
(a member of the Sandoz Group)

Reference Project Proprietary technology

National research programme
“Cell Physiology”

Published References Proprietary technology

A list of peer-reviewed scientific
papers by the head the programme
“Cell physiology”.

Videolectures
Clinical Trials

Autologous hybridomas
(EudraCT # 2012-005498-29)

Latest / May 7th, 2014 / CELICA BIOMEDICAL publishes a milestone study on Vesicle Architecture and Synaptobrevin2 in Astrocytes. www.nature.com